{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:14:04Z","timestamp":1768511644694,"version":"3.49.0"},"posted":{"date-parts":[[2024,4,7]]},"group-title":"Microbiology","reference-count":20,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                  is the primary etiological agent of aspergillosis. Here, we show that the host defense peptide mimetic, brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of\n                  <jats:italic>A. fumigatus<\/jats:italic>\n                  . CAS-resistant strains with mutations in\n                  <jats:italic>fks1<\/jats:italic>\n                  that encodes the 1,3-\u03b2-D-glucan synthase are not IBX-resistant and BRI+IBX can inhibit their growth. The combination of BRI+IBX plays a fungicidal role, increases the fungal cell permeability and decreases the fungal survival in the presence of A549 epithelial cells.\n                <\/jats:p>","DOI":"10.1101\/2024.04.05.588305","type":"posted-content","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T11:25:12Z","timestamp":1712489112000},"source":"Crossref","is-referenced-by-count":0,"title":["Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus\n                  <i>Aspergillus fumigatus<\/i>"],"prefix":"10.64898","author":[{"given":"Thaila Fernanda","family":"dos Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Figueiredo","family":"Pinzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Alves","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2986-350X","authenticated-orcid":false,"given":"Gustavo H.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024040914053179000_2024.04.05.588305v1.1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00140-18"},{"key":"2024040914053179000_2024.04.05.588305v1.2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2024040914053179000_2024.04.05.588305v1.3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","article-title":"Ibrexafungerp: first approval","volume":"81","year":"2021","journal-title":"Drugs"},{"key":"2024040914053179000_2024.04.05.588305v1.4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2023.2203383","article-title":"The antifungal pipeline for invasive fungal diseases: what does the future hold ?","volume":"21","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024040914053179000_2024.04.05.588305v1.5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2147\/IDR.S375625","article-title":"Novel therapeutic approaches to invasive candidiasis: considerations for the clinician","volume":"16","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2024040914053179000_2024.04.05.588305v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2008.10.013"},{"key":"2024040914053179000_2024.04.05.588305v1.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811818106"},{"key":"2024040914053179000_2024.04.05.588305v1.8","doi-asserted-by":"publisher","DOI":"10.1021\/ar900036b"},{"key":"2024040914053179000_2024.04.05.588305v1.9","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2020-0048"},{"key":"2024040914053179000_2024.04.05.588305v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37573-y"},{"key":"2024040914053179000_2024.04.05.588305v1.11","doi-asserted-by":"crossref","first-page":"119647","DOI":"10.1016\/j.lfs.2021.119647","article-title":"Synthetic antimicrobial peptides: Characteristics, design, and potential as alternative molecules to overcome microbial resistance","volume":"278","year":"2021","journal-title":"Life Sci"},{"key":"2024040914053179000_2024.04.05.588305v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.13696"},{"key":"2024040914053179000_2024.04.05.588305v1.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082046199"},{"key":"2024040914053179000_2024.04.05.588305v1.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02955-14"},{"key":"2024040914053179000_2024.04.05.588305v1.15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/jop.2015.0098","article-title":"An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective","volume":"32","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"2024040914053179000_2024.04.05.588305v1.16","first-page":"e00833","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040914053179000_2024.04.05.588305v1.17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","year":"2020","journal-title":"Med Mycol"},{"key":"2024040914053179000_2024.04.05.588305v1.18","first-page":"e00244","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040914053179000_2024.04.05.588305v1.19","first-page":"e02429","article-title":"Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1?3)-\u03b2-d-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040914053179000_2024.04.05.588305v1.20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/jof8111121","article-title":"Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections","volume":"8","year":"2022","journal-title":"J Fungi"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.04.05.588305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:14:57Z","timestamp":1768457697000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.04.05.588305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1101\/2024.04.05.588305","relation":{},"subject":[],"published":{"date-parts":[[2024,4,7]]},"subtype":"preprint"}}